Data presented at the recent European Conference on Clinical Aspects and Treatment of HIV Infection in Athens holds promise that medications being developed to combat multi-drug resistant HIV are nearing the market. The most recent analyses show that around 25% of patients undergoing antiretroviral therapy have developed multi-drug resistant HIV, and that the overall prevalence of resistance is growing (Nature Med. 7, 1016; 2001).
Phase II trials of T-20, a fusion inhibitor developed by North Carolina-based biotech company, Trimeris, reduced viral load by at least 10-fold in 56% of patients receiving treatment. Results from Phase III studies are expected in the Spring.
T-20 targets HIV as its membrane fuses with the membrane of a host cell—a critical step in viral entry. Trimeris is developing a second-generation drug (T-1249) which is roughly two years behind T-20 in the development pipeline. Because T-20 and T-1249 are small peptides that target the viral protein gp41, the differences in their resistance profiles suggest that engineering changes to peptide drugs may provide a rapid means of responding to new waves of viral resistance. In addition, preliminary evidence suggests that fusion inhibitors and other inhibitors of viral entry, such as compounds that block virus-receptor interactions, may act synergistically.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Dove, A. New class of HIV drugs shows promise. Nat Med 7, 1265 (2001). https://doi.org/10.1038/nm1201-1265b
Issue Date:
DOI: https://doi.org/10.1038/nm1201-1265b